<DOC>
	<DOCNO>NCT00121186</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine melphalan , donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus methotrexate transplant may stop happen . PURPOSE : This phase II trial study well give fludarabine together melphalan follow tacrolimus methotrexate work treat patient undergo donor stem cell transplant relapse lymphoma .</brief_summary>
	<brief_title>S0501 Fludarabine , Melphalan , Donor Stem Cell Transplant Followed By Tacrolimus Methotrexate Treating Patients Relapsed Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine 1-year progression-free overall survival rate patient relapse Hodgkin 's non-Hodgkin 's lymphoma prior autologous stem cell transplantation treat nonmyeloablative conditioning regimen comprise fludarabine melphalan follow allogeneic bone marrow peripheral blood stem cell transplantation immunosuppression comprise tacrolimus methotrexate . - Determine treatment-related mortality patient treat regimen . - Determine toxic effect regimen patient . - Determine engraftment donor hematopoietic stem cell , measure hematopoietic recovery donor-derived hematopoiesis ( determine T cell neutrophil specific chimerism ) 2 , 3 , 6 , 12 month , patient treat regimen . - Determine incidence acute chronic graft-versus-host disease patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord diagnosis ( Hodgkin 's lymphoma vs non-Hodgkin 's lymphoma ) . Patients receive fludarabine IV 1 hour day -6 -2 melphalan IV 15-20 minute day -3 -2 . Patients undergo allogeneic peripheral blood stem cell bone marrow transplantation day 0 . Patients receive oral tacrolimus twice daily begin day -3 continue day 100 follow taper day 180 . Patients also receive methotrexate IV day 1 , 3 , 7 . Treatment continue absence disease progression unacceptable toxicity . After completion study transplantation , patient follow 1 3 month , 1 year , annually 4 year . PROJECTED ACCRUAL : A total 50 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis lymphoma 1 follow type : Diffuse large Bcell lymphoma Follicular lymphoma Grades 1 , 2 , 3 Primary mediastinal lymphoma Mantle cell lymphoma Small lymphocytic lymphoma Hodgkin 's lymphoma Transformed lymphoma Relapsed prior autologous bone marrow transplantation ( BMT ) More 180 day post BMT Received ≥ 1 course chemotherapy BMT relapse Achieved complete response OR partial response chemotherapy Largest residual tumor dimension ≤ 2 cm No clinical laboratory evidence CNS involvement lymphoma HLAidentical donor available , meet 1 follow criterion : Sibling donor 5/6 6/6 allele match genotyping No monozygotic identical twin Unrelated donor 10/10 allele match genotyping PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular LVEF ≥ 40 % MUGA 2D echocardiogram ( 2D ECHO ) No significant cardiac abnormality MUGA 2D ECHO No uncompensated coronary artery disease ECG physical exam None follow within past 6 month : Myocardial infarction Unstable angina Uncontrolled atrial fibrillation None follow within past 3 month : Severe peripheral vascular disease Venous stasis ulcer Deep venous arterial thrombosis No uncontrolled hypertension Pulmonary DLCO ( correct ) total lung capacity ≥ 40 % predict No requirement continuous supplemental oxygen Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No AIDS No active bacterial , viral , fungal infection No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No history uncontrolled seizures No diabetic ulcer within past 3 month PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No 1 prior bone marrow transplantation Chemotherapy See Disease Characteristics More 21 day since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy Surgery More 4 week since prior major surgery except placement venous access device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>